Tag Archives: Research and Development

What Will It Take for the U.S. to Maintain Leadership in the Biopharma Industry?

deborah

The biopharmaceutical industry is an important contributor to U.S. economic growth and sustainability, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic output that totals more than $900 billion.[i] This significant economic impact is due to the high value-added nature of the sector, its extensive supply chain relationships, and high-wage jobs. As a result, gains and losses in the biopharmaceutical sector cascade across many important economic sectors Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO 2012 Super Session Recap: Ernst & Young’s Beyond Borders

Ernst & Young

The fanfare surrounding this morning’s unveiling of Ernst & Young’s 26th annual report on the state of the biotech industry, Beyond Borders, was buoyed by positive trends outlined in the report that show despite the overall lingering uneasiness in the economy, biotech is continuing its growth momentum. The Super Session at the 2012 BIO International Convention was moderated by members of Ernst & Young’s life sciences leadership team: Glen Giovannetti, Gautam Jaggi and Sanjeev Wadhwa; Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Five Keys to Making Biotech Flourish in China

baier-china

As China positions itself as a major global player in the international biotechnology arena, it has included biotechnology as one of the seven strategic priorities for scientific and technological development in its 12th Five-year Plan. During the keynote lunch of the China Day special program at the 2012 BIO International Convention, David W. Beier, senior vice president at Amgen and former chief domestic policy advisor to Vice President Al Gore, outlined the 5 keys to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation

ticker

The Tuesday plenary luncheon at the 2012 BIO CEO & Investor Conference featured a panel of experts representing several perspectives on valuation. The session opened with Ben Bonifant, Senior Vice President & Practice Area Leader at Campbell Alliance, presenting results from their Corporate Value Study, which was followed by a discussion examining the key value drivers for emerging companies. Bonifant moderated the panel discussion that featured: Rachel K. King, Chief Executive Officer, GlycoMimetics, Inc. Michael Margolis, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Fireside Chat with Dr. Mikael Dolsten

Dolsten

Day two of the BIO CEO & Investor Conference kicked off with a Fireside Chat featuring Mikael Dolsten, MD, Phd, president, worldwide research & development from Pfizer, Inc and moderated by Mark Schoenebaum, senior biotechnology analyst with ISI Group. Speaking to a full room, Dr. Dolsten touched on Pfizer’s R&D priorities and their increased efforts to focus on investor capital return through a strong mixture of science, business and financial endeavors. In focusing on R&D, Pfizer has Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,